National Cord Blood Inventory Contract Exceeds $57.9M, Awarded to UT MD Anderson

Contract Overview

Contract Amount: $57,937,279 ($57.9M)

Contractor: THE Univeristy of Texas M.D. Anderson Cancer Center

Awarding Agency: Department of Health and Human Services

Start Date: 2019-09-27

End Date: 2035-09-03

Contract Duration: 5,820 days

Daily Burn Rate: $10.0K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 6

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: NATIONAL CORD BLOOD INVENTORY

Place of Performance

Location: HOUSTON, HARRIS County, TEXAS, 77030

State: Texas Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $57.9 million to THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER for work described as: NATIONAL CORD BLOOD INVENTORY Key points: 1. Significant investment in a critical national resource. 2. Potential for high value in medical research and treatment. 3. Long-term contract duration raises questions about ongoing need and cost-effectiveness. 4. Health and Human Services is the primary agency. 5. Focus on blood and organ banks sector.

Value Assessment

Rating: fair

The contract value of $57.9M over its term is substantial. Benchmarking against similar national inventory or bio-repository contracts is difficult due to the unique nature of cord blood. Further analysis of the per-unit cost or service delivery metrics would be needed for a more precise valuation.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, suggesting a competitive bidding process. However, the long duration and specific nature of the service may limit the number of truly competitive bids received over time. Price discovery is likely influenced by the specialized requirements.

Taxpayer Impact: Taxpayers are funding a critical national asset for public health. The long-term commitment implies a sustained investment, the ultimate return on which depends on the utilization and success of the cord blood inventory.

Public Impact

Ensures a national supply of cord blood for potential life-saving treatments and research. Supports advancements in regenerative medicine and disease treatment. Provides a critical resource for public health emergencies. Potential for long-term medical breakthroughs. Benefits patients requiring stem cell transplants.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Positive Signals

Sector Analysis

This contract falls within the Health and Human Services sector, specifically related to bio-repository and blood banking services. Spending benchmarks for national-scale cord blood inventories are scarce due to their unique nature, but this represents a significant investment in a specialized area of healthcare.

Small Business Impact

The provided data does not indicate any specific set-asides for small businesses. Given the scale and specialized nature of the National Cord Blood Inventory, it is likely that larger, specialized organizations are better positioned to compete for and manage such a contract.

Oversight & Accountability

The Health Resources and Services Administration (HRSA) is responsible for overseeing this contract. The long duration necessitates robust oversight to ensure continued relevance, cost-effectiveness, and adherence to scientific and ethical standards throughout the contract period.

Related Government Programs

Risk Flags

Tags

blood-and-organ-banks, department-of-health-and-human-services, tx, definitive-contract, 10m-plus

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $57.9 million to THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER. NATIONAL CORD BLOOD INVENTORY

Who is the contractor on this award?

The obligated recipient is THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Health Resources and Services Administration).

What is the total obligated amount?

The obligated amount is $57.9 million.

What is the period of performance?

Start: 2019-09-27. End: 2035-09-03.

What is the projected utilization rate of the cord blood inventory over the contract's lifespan, and how does this inform the value proposition?

The projected utilization rate is crucial for assessing the contract's value. A low utilization rate might indicate over-investment or a lack of demand, questioning the efficiency of the $57.9M expenditure. Conversely, high utilization for critical treatments or research would strongly justify the investment, demonstrating significant public health impact and return on taxpayer funds.

What are the specific risks associated with maintaining a national cord blood inventory for over 16 years, and how are they being mitigated?

Risks include biological degradation of samples, evolving scientific standards for storage and processing, and potential obsolescence of technology. Mitigation strategies likely involve stringent quality control, regular protocol updates based on scientific advancements, and contingency plans for sample management and data security. The long duration necessitates proactive risk management.

How effectively is the National Cord Blood Inventory contributing to medical research and patient treatment outcomes compared to alternative approaches?

Effectiveness is measured by the number of successful transplants, research breakthroughs enabled, and lives saved or improved. Comparing this to alternative stem cell sources or decentralized inventory models is essential. Data on the inventory's specific contributions to published research and clinical applications would provide concrete evidence of its impact and justify the substantial federal investment.

Industry Classification

NAICS: Health Care and Social AssistanceOther Ambulatory Health Care ServicesBlood and Organ Banks

Product/Service Code: MEDICAL SERVICESMEDICAL, DENTAL, AND SURGICAL SVCS

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 19250SOL00062

Offers Received: 6

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 1515 HOLCOMBE BLVD UNIT 207, HOUSTON, TX, 77030

Business Categories: Category Business, Educational Institution, Government, Higher Education, Hospital, U.S. National Government, Not Designated a Small Business, Higher Education (Public), U.S. Regional/State Government, Special Designations

Financial Breakdown

Contract Ceiling: $62,742,484

Exercised Options: $57,937,279

Current Obligation: $57,937,279

Actual Outlays: $32,715,099

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline

Start Date: 2019-09-27

Current End Date: 2035-09-03

Potential End Date: 2035-09-03 00:00:00

Last Modified: 2025-12-04

More Contracts from THE Univeristy of Texas M.D. Anderson Cancer Center

View all THE Univeristy of Texas M.D. Anderson Cancer Center federal contracts →

Other Department of Health and Human Services Contracts

View all Department of Health and Human Services contracts →

Explore Related Government Spending